Clinical Data Fraud Involving CROs Attracting US Justice Department Attention
Executive Summary
Submission of manipulated clinical data to support product approval is a ‘major concern’ for the DoJ, consumer protection branch director Gusav Eyler says, adding that some of the problems relate to outsourcing of trials. Also, DoJ and HHS OIG are using data analytics to identify outliers in prescribing and reimbursement claims.
You may also be interested in...
Data Integrity ‘More Than Just A GMP Issue’ As Attention To Clinical, Nonclinical Lapses Grows
Sponsors should notify US FDA quickly when they detect data quality issues in preclinical and clinical research, particularly for applications under review, experts say in a rebuke to Novartis’ delayed notification about Zolgensma data manipulation.
Teva And Cipla Will Have ANDAs Withdrawn
Watson (now Teva) and InvaGen (now Cipla) failed to submit new bioequivalence data following enforcement action against Cetero Research.
After Ignoring Letters From US FDA, Teva And Cipla Will Have ANDAs Withdrawn
Watson (now Teva) and InvaGen (now Cipla) failed to submit new bioequivalence data following enforcement action against Cetero Research.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: